drugset / Trial / NCT02181257

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary aims of this study is to determine the efficacy and tolerability of Extracorporeal Photopheresis (ECP) for the treatment of either Refractory Bronchiolitis Obliterans Syndrome (BOS) patients (258 at cessation of enrollment April 7, 2022) or Newly Diagnosed (22 as of enrollment Hold February 2022) Bronchiolitis Obliterans Syndrome patients after lung transplantation. In compliance with the Centers for Medicare and Medicaid Services' (CMS) Coverage with Evidence Development (CED) decision, the study will collect specified demographic, comorbidity, treatment, and outcome data exclusively for Medicare beneficiaries who are treated with ECP for either refractory or New BOS.

Timeline

Start
2015-01
Primary completion
2027-04
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Background Methoxsalen Other / unclassified